Seattle Genetics (SGEN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) PT Cut at BofA/Merrill Lynch on Lower Adcetris Sales
February 11, 2015 6:57 AM ESTBofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating while lowering estimates and his price target on Seattle Genetics (NASDAQ: SGEN) to $33.00 (from $35.00) on cautious Adcetris sales.
Byrne notes Adcetris guidance represents around 15% year-over-year growth. Meanwhile, the analyst sees 2015 U.S.... More
